The North American Freshwater Turtle Research Group (NAFTRG): An undergraduate research experience (URE) and citizen scientist project

Researchers today understand the importance of incorporating undergraduate research experiences (URE) and citizen-science methods into data collection and long-term research projects. The North American Freshwater Turtle Research Group (NAFTRG) is an example of a project in which both methods are implemented. The NAFTRG conducts long-term studies on turtle populations in seven state park springs in Florida and the largest freshwater spring in Texas. Although the study began as an undergraduate biology class, it has expanded throughout the years into a study that many parks and researchers rely upon for important data on turtle populations and for information that helps manage the stability of ecosystems. Through the use of UREs, the research investigators are enabling undergraduates to gain valuable research experiences while maintaining a volunteer base that has a vested interest in the study itself. Students from Pennsylvania State University, University of North Florida, Peninsula College, Freed-Hardeman University, and Western Washington University have chosen to participate in the study. Many of these students have volunteered additional time and efforts during subsequent research trips. A project of this nature enables students to see the importance of ecosystem awareness. Through the use of citizen science, investigators can form a large volunteer base while incorporating sophisticated ecological methodologies and furthering coonservation efforts. Many participating citizen scientists have jobs unrelated to the sciences; they volunteer their time because they understand the importance of the group’s objectives and are willing to support them with their time and energy. Our current volunteer base receives further support from local zoos, aquariums, amusement parks, and the public. Based on standardized values for volunteer work, citizen scientists and donations from governmental and non-governmental organizations have contributed approximately one million dollars to this project. Citizen science is helping to bridge the gap between the general public and the scientific community by allowing the two to work together in monitoring, managing, maintaining, and understanding the ecological issues around us. &nbsp

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to < 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of & GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P < 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo